Registration
Registration for this program is now closed. Walk-in attendees are welcome the day of the program. Only credit card payments will be accepted on site.

DCAT is pleased to offer the fifth installment of its successful international business development series. This three-hour program is followed by a reception during which program participants are invited to meet the speakers and other attendees. Both the program and reception are provided for a fee of $79.00 to DCAT member company representatives. The non-member fee for attendance is $139.00. Registration is available online only. Seating is limited and is on a first-come, first-served basis.

This year’s forum, “Pharmaceutical Manufacturing: The Next Wave of Transformation,” will examine the latest wave of transformative activity that is reshaping the global pharmaceutical supply chain: downsizing and plant sales by large multinationals, growth and acquisitions by companies from developing countries and technological/regulatory drivers for change such as the advent of biopharmaceuticals. Leading consultants and company representatives will share their perspective on new ways to extract value through sourcing in the new environment.

Program topics will include:

Overview of Recent Transaction Activity, Drivers and Trends
William Wiederseim, President & CEO, PharmaBioSource, Blue Bell, PA
This discussion will provide an overview of recent industry activities and trends such as the re-surfacing of the US vaccine business and India's emergence as the world's most aggressive acquirer of life sciences sites. Mr. Wiederseim will provide specific examples of site acquisition and disposition trends and strategies, and will discuss why a leading manufacturer has decided to exit the outsourcing business.

Divesting Pharma Manufacturing Assets - Pfizer Inc.
Charles M. Shafran, Vice President, Strategic Planning, Pfizer Global Manufacturing, NY, NY
Many of the major pharmaceutical companies are looking to rationalize their plant networks as their major products come off patent and are not being replaced by similarly large scale products. Active Pharmaceutical Ingredient (API) capacity is also in excess, even with new products as the trend to more potent APIs reduces significantly the amount required to service the market. Pfizer has eliminated or announced the elimination of more than 50% of its manufacturing facilities and in many cases has sought the sale of these sites as going entities to both preserve employment opportunities for its colleagues and to sustain the business for the local communities in which these plants are located.

Mr. Shafran will discuss the manner in which Pfizer decides which plants should be eliminated from its network, how to market the site and the types of transactions that it has been able to develop and negotiate in the aftermath of the Warner-Lambert Merger, the Pharmacia acquisition and the acquisition of several other plant sites/small companies. Learn how Pfizer’s rationalization impacts the API and pharmaceutical sourcing environment.

Acquisition Case Studies and their Implications on the Sourcing Environment

Aesica Pharmaceuticals Limited, Cramlington, United Kingdom
Adam Sims, Finance Director
The API business is fragmented as big pharma companies are starting to divest, while low cost competition is arriving from India/China. In this session, hear how this well-established supplier of APIs acquired two API facilities in the past 3 years. Learn how Aesica’s acquisitions have streamlined the manufacturing process and how the company is responding to the changing demands of its customers and the environment.

Nicholas Piramal, Mumbai, India
R. "Ananth" Ananthanarayanan, Ph.D., President, NPIL Pharma, Inc
Nicholas Piramal continues to grow the custom development & manufacturing business via organic and inorganic strategies. Over the last three years, acquisitions of Rhodia Organique's Inhalation anesthetics business, Avecia Pharmaceuticals, and Pfizer's Morpeth Manufacturing facility have propelled them into the top ten CMOs. Learn about their acquisition strategy which centers around long-term partnerships, investment and growth in technology, and how they utilize geography and assets to their advantage. Hear how the combination of India-based low-cost manufacturing coupled with strong technology and global presence lays the groundwork for a well-positioned customer offering for both APIs and finished dosage forms.

Aptuit, Kansas City, Missouri  
Frank J. Wright, COO and Co-Founder
Stuart Needleman, Senior Director, API Development
In this session, learn how Aptuit has emerged as one of the pharmaceutical industry's leading contract service providers. Hear how the company evolved as its founders sought to engineer a better drug development process as a result of lessons learned from leadership experience at ChiRex and Rhodia Pharmasolutions.

Speakers’ Roundtable Discussion
An interactive forum of questions and answers by audience members and the program’s speakers.

Registration for this program is now closed. Walk-in attendees are welcome the day of the program. Only credit card payments will be accepted on site.

About our Speakers:
R. Ananthanarayanan (Ananth), President and Director on the Board, NPIL Pharma Inc., a 100% wholly owned subsidiary of Nicholas Piramal India Limited, is responsible for the global business of the custom manufacturing division of Nicholas Piramal India Limited. Dr. Ananthanarayanan has been involved in formulating NPIL’s international strategy and has worked as a part of their senior management in building the business with respect to their custom manufacturing strategy as well as mergers and acquisition. In his industry experience, he has worked in various functions such as product development, quality, regulatory affairs, manufacturing operations, global outsourcing and business development. He was responsible for successfully setting up effective sourcing for bulk actives and finished dosage forms from Asia, Europe and the US. He holds a Ph.D. in Pharmaceutical Technology from the University of Mumbai, India and has over 16 years of experience in the pharmaceutical industry in India and abroad.

Stuart Needleman has more than 20 years experience in drug development, with a specialisation in the global development, scale-up, and manufacture of regulated active pharmaceutical ingredients (API) for new and established compounds. Mr. Needleman joined Aptuit in early 2006 as Senior Director, Active Pharmaceutical Ingredient Development to build the company’s API development and manufacture offering.  Mr. Needleman has most recently assumed the position of Senior Director, Sales and Marketing at Aptuit.

Over the course of his career, Mr. Needleman has worked for Cambrex, Oxford Asymmetry for whom he created a significant North American presence, ChiRex Inc. as Vice President Business Development, Rhodia Pharma Solutions as General Manager Development Operations, and most recently, as President, North America for Arch Pharmalabs with headquarters and manufacturing operations in India. Mr. Needleman received an MBA and a BSc in Chemical Engineering from Rensselaer Polytechnic Institute.

Charles Shafran, Vice President of Strategic Planning, Pfizer Global Manufacturing began his career with Pfizer in 1971 at the Groton, Connecticut, plant, where he was responsible for the manufacture of bulk antibiotics. He moved to Pfizer's N.Y. headquarters in 1975 and worked in the specialty chemicals and minerals businesses, moving to Pfizer's U.S. pharmaceuticals manufacturing organization in 1982 as director of engineering. He was named director of manufacturing information management systems when Pfizer integrated its worldwide manufacturing business in 1997. In early 2000 he led the integration of the Pfizer and Warner-Lambert manufacturing operations, assuming the role of vice president of strategic planning. This role has evolved to include leading post-merger integration activities and other initiatives, including the ongoing integration of the Pfizer and Pharmacia manufacturing networks and the sale of Pfizer's consumer healthcare business to Johnson & Johnson.

Mr. Shafran holds B.S. and M.Eng. degrees in chemical engineering from Cornell University and an M.B.A. from the University of Connecticut. He is also a member of the Advisory Council to the School of Chemical and Biomolecular Engineering in the College of Engineering at Cornell University.

Adam Sims, B.Eng., ACA, Chief Financial Officer, Aesica Pharmaceuticals is an engineer who became an accountant, with many years experience in the pharmaceutical industry with both BASF and latterly with Aesica Pharmaceuticals. Currently Mr. Sims is responsible for all of Aesica's finance and procurement activities, including site acquisition and integration into the Aesica pharmaceuticals family.  Prior to his experience in the pharmaceutical industry Mr. Sims trained with KPMG as a UK chartered accountant in both London and San Francisco.

Frank Wright, Chief Operating Officer, Aptuit has more than 30 years of experience in the chemical and pharmaceutical industries.  Mr. Wright was formerly Vice President, Corporate Development of ChiRex, Inc.  Prior to joining ChiRex, Mr. Wright held senior positions with GlaxoWellcome for 15 years.  

William Wiederseim, President & CEO, PharmaBioSource has been a consultant to the pharmaceutical, chemical and automotive industries for more than twenty years. He is the co-founder and First Executive Director of The Consortium for the Advancement of Manufacturing in Pharmaceuticals (CAMP), a non-profit research consortium for the Pharmaceutical Industry, MIT and Purdue University.  Mr. Wiederseim is the founder and primary person responsible for the overall development of PharmaBioSource.